This trial is evaluating whether Treatment will improve 3 primary outcomes and 3 secondary outcomes in patients with Acute Lymphoblastic Leukemia (ALL). Measurement will happen over the course of Baseline and 6-month follow-up.
This trial requires 104 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are not being studied for commercial purposes.
Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.
In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.